Celon Pharma S.A.

CLN

PLCLNPH00015

Pharmaceuticals

Market Closed - Warsaw S.E. Other stock markets 11:55:43 2024-04-26 am EDT			5-day change	1st Jan Change
15.24 ^PLN	+1.87%		+3.11%	-1.42%

Apr. 24	Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Celon Pharma Successfully Completes the First Stage of Clinical Research into its CPL'116 Drug Candidate for Treating Autoimmune Diseases

August 10, 2021 at 11:02 am EDT

Celon Pharma successfully completed the first stage of clinical research into its CPL'116 drug candidate for treating autoimmune diseases, the company said in a market filing.

Latest news about Celon Pharma S.A.

Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-20	CI
Celon Pharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-23	CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-28	CI
Celon Pharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-25	CI
Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-01	CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-09-30	CI
Celon Pharma Successfully Completes the First Stage of Clinical Research into its CPL'116 Drug Candidate for Treating Autoimmune Diseases	21-08-10	CI
Celon Pharma to Raise PLN 216mn in Public Offering	21-07-11	CI
Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes	21-06-22	CI
Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial	21-04-01	CI
Celon Pharma Seeks Partner for Salmex	21-03-04	CI
Celon Pharma Terminates Cooperation with Lupin Atlantis Holdings	21-03-02	CI
Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor	21-02-10	CI
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression	21-01-08	CI
Celon Pharma S.A. Announces Earnings Results for the Third Quarter Ended September 30, 2020	20-11-30	CI
Celon Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-25	CI
Celon Pharma S.A.(WSE:CLN) added to S&P Global BMI Index	20-09-21	CI
Celon Pharma S.A.(WSE:CLN) dropped from S&P Global BMI Index	19-09-23	CI
Celon Pharma S.A.(WSE:CLN) added to S&P Global BMI Index	17-03-20	CI
Celon Pharma S.A. has completed an IPO in the amount of PLN 244.95 million.	16-09-28	CI

Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Celon Pharma S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

15.24 PLN

Average target price

16.5 PLN

Spread / Average Target

+8.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CELON PHARMA S.A.	-1.42%	192M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Celon Pharma S.A.

Equities

CLN

PLCLNPH00015

Pharmaceuticals

Celon Pharma Successfully Completes the First Stage of Clinical Research into its CPL'116 Drug Candidate for Treating Autoimmune Diseases

Latest news about Celon Pharma S.A.

Chart Celon Pharma S.A.

Company Profile

Income Statement Evolution

Ratings for Celon Pharma S.A.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals